Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 16/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825907 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAAL3MBTL1NPC1RAB9A | |
| SCHEMBL4831198 | 0.80 | PGR (0.42) | ALDH1A1SMN1; SMN2GRM5 | |
| SCHEMBL963861 | 0.80 | ALDH1A1 (0.51) | ALDH1A1GAAL3MBTL1NPC1RAB9A | |
| SCHEMBL963863 | 0.80 | ALDH1A1 (0.51) | ALDH1A1GAAL3MBTL1NPC1RAB9A | |
| SCHEMBL21981602 | 0.76 | CYP1A2 (0.50) | GRM5MAPT | |
| SCHEMBL4825815 | 0.75 | CCNC (0.49) | ALDH1A1NPC1RAB9ASMN1; SMN2GRM5 | |
| SCHEMBL4833832 | 0.75 | CCNC (0.49) | ALDH1A1NPC1RAB9ASMN1; SMN2GRM5 | |
| SCHEMBL4825825 | 0.75 | CCNC (0.49) | ALDH1A1NPC1RAB9ASMN1; SMN2GRM5 | |
| SCHEMBL4825853 | 0.74 | GRM5 (0.42) | ALDH1A1GAASMN1; SMN2GRM5MAPT | |
| SCHEMBL4825840 | 0.74 | GRM5 (0.42) | ALDH1A1GAASMN1; SMN2GRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | ALDH1A1 2652/4885GAA 4645/4885L3MBTL1 3524/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | ALDH1A1 2652/4885GAA 4645/4885L3MBTL1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.